These results suggest that while downregulation of both c-Myc and Mcl-1 are important contributors to voruciclib’s enhancement of venetoclax activity in AML cells, c-Myc may be more important than Mcl-1. The gene discussed is MCL1; the disease is acute myeloid leukemia.